Department of Endocrinology, Baoding NO.1 Central Hospital, Baoding, Hebei, People's Republic of China.
Metab Syndr Relat Disord. 2021 Sep;19(7):367-371. doi: 10.1089/met.2020.0141. Epub 2021 May 3.
The global increase of obesity parallels the obesity-related glomerulopathy (ORG) epidemic. The purpose of this review is to emphasize the potential therapeutic targets of ORG as well as the corresponding possible mechanisms. We systematically identified surveys, reports, and published studies that included data for the purpose of this review and did literature analysis. Under circumstance of obesity, weight loss, and renin-angiotensin-aldosterone blockade are the most studied therapies, effective to induce antiproteinuric effects and reversal of hyperfiltration in ORG. Glucagon-like peptide-1-based therapies led to improvement in proteinuria. Newer therapies directed to lipid metabolism, including farnesoid X receptor and takeda G protein-coupled receptor 5 agonists, peroxisome proliferator-activated receptor α agonists, hold therapeutic promise. Prevention and treatments of obesity and ORG are of great importance.
肥胖的全球化与肥胖相关的肾小球病（ORG）流行并行不悖。本综述的目的是强调 ORG 的潜在治疗靶点以及相应的可能机制。我们系统地确定了调查、报告和已发表的研究，这些研究包含了本次综述的目的的数据，并进行了文献分析。在肥胖的情况下，减肥和肾素-血管紧张素-醛固酮阻断是研究最多的疗法，可有效诱导 ORG 的蛋白尿效应和超滤的逆转。基于胰高血糖素样肽-1 的疗法可改善蛋白尿。针对脂质代谢的新型疗法，包括法尼醇 X 受体和武田 G 蛋白偶联受体 5 激动剂、过氧化物酶体增殖物激活受体α激动剂，具有治疗潜力。肥胖和 ORG 的预防和治疗非常重要。
